DNA blood test could guide lung cancer treatment, reducing chemo
NCT ID NCT07058519
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized approach for people with advanced EGFR-mutant lung cancer. After initial treatment with osimertinib plus chemotherapy, doctors will use a blood test (ctDNA) to decide if patients can stop chemotherapy and continue with osimertinib alone, or if they need both drugs. The goal is to see if this adaptive strategy can keep cancer under control while reducing chemotherapy exposure. The trial involves 250 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Osimertinib (a targeted cancer drug) and chemotherapy (pemetrexed)
- What this could lead to
- If successful, this could lead to a more personalized treatment approach for advanced lung cancer, potentially reducing chemotherapy side effects while maintaining disease control.
- What could go wrong
- This is a phase 2 trial with only 250 participants, so results are preliminary. The adaptive strategy may not improve survival, and some patients may still experience disease progression or side effects from the drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC EGFRM NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 200030, China